ReviewCurrent stem cell research & therapy2010
Epigenetic remodeling of chromatin architecture: exploring tumor differentiation therapies in mesenchymal stem cells and sarcomas.
Review in Current stem cell research & therapy, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 39 citations in OpenAlex.
- Targeting cancer stem cells by TPA leads to inhibition of refractory sarcoma and extended overall survival.Molecular therapy. Oncology · 2024Article
- Engaging plasticity: Differentiation therapy in solid tumors.Frontiers in pharmacology · 2022Review
- Autologous cell-based therapy for treatment of large bone defects: from bench to bedside.European journal of trauma and emergency surgery : official publication of the European Trauma Society · 2018Review
- Exploring the Histogenesis and Diagnostic Strategy Using Immunoassay and RT-PCR in Alveolar Soft Part Sarcoma.Pathology oncology research : POR · 2018Article
- Epigenetic Contribution of High-Mobility Group A Proteins to Stem Cell Properties.International journal of cell biology · 2018Review
- Review
- Epigenetic Regulation of Carotid Body Oxygen Sensing: Clinical Implications.Advances in experimental medicine and biology · 2015Review
- Role of epigenetic modulation for the treatment of sarcoma.Current treatment options in oncology · 2013Article
- Terminal differentiation and loss of tumorigenicity of human cancers via pluripotency-based reprogramming.Oncogene · 2013Article
- Article
- The ablation of EZH2 uncovers its crucial role in rhabdomyosarcoma formation.Cell cycle (Georgetown, Tex.) · 2012Article
- Solid tumor differentiation therapy - is it possible?Oncotarget · 2012Review
- Enhancer of zeste homolog 2 (EZH2) in pediatric soft tissue sarcomas: first implications.BMC medicine · 2011Review
- Cancer cells' epigenetic composition and predisposition to histone deacetylase inhibitor sensitization.Epigenomics · 2011Review
- Chromatin structure predicts epigenetic therapy responsiveness in sarcoma.Molecular cancer therapeutics · 2011Article
- Epigenetic regulation of mesenchymal stem cells: a focus on osteogenic and adipogenic differentiation.Stem cells international · 2011Article
- Cell therapy in bone healing disorders.Orthopedic reviews · 2010Article
- [Cell therapy in bone-healing disorders].Der Orthopade · 2010Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Sarcomas are the mesenchymal-derived malignant tumors of connective tissues (e.g., fat, bone, and cartilage) presumed to arise from aberrant development or differentiation of mesenchymal stem cells (MSCs). Appropriate control of stem cell maintenance versus differentiation allows for normal connective tissue development. Current theories suggest that loss of this control--through accumulation of genetic lesions in MSCs at various points in the differentiation process--leads to development of sarcomas, including undifferentiated, high grade sarcoma tumors. The initiation of stem cell differentiation is highly associated with alteration of gene expression, which depends on chromatin remodeling. Epigenetic chromatin modifying agents have been shown to induce cancer cell differentiation and are currently being used clinically to treat cancer. This review will focus on the importance of epigenetic chromatin remodeling in the context of mesenchymal stem cells, sarcoma tumorigenesis and differentiation therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.